Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR1015-A (Fimasartan/Indapamide) in Healthy Volunteers
NCT07421388Phase 1Not yet recruiting
- Sponsor
- Boryung
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of fimasartan and indapamide in essential hypertension (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve of Fimasartan at 48 hours, Area Under the Curve of Indapamide at 72 hours and 2 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
fimasartanindapamide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07421388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421388.